Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)

Scottish Medicines Consortium
Record ID 32018000967
English
Authors' objectives: To assess the clinical and cost effectiveness.
Details
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Scotland
MeSH Terms
  • Spondylarthritis
  • Spondylitis, Ankylosing
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
Contact
Organisation Name: Scottish Medicines Consortium (SMC)
Contact Address: Delta House | 50 West Nile Street
Contact Name: Susan Downie
Contact Email: susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.